Drug profile · INN
lanadelumab
TAKHZYRO
lanadelumab (TAKHZYRO) is a plasma kallikrein inhibitor. Associated with Lacuna Pharma Pty Ltd.
EMA: approved TGA: approved Blood and blood forming organs (B06) B06AC05
Patents linked 0
Pipeline programs 6
News articles 0
Drug details — lanadelumab
- Class
- Blood and blood forming organs (B06)
- Route
- —
- Patents
- 0
- Programs
- 6
- Data quality
- 0.89
Quick answer
lanadelumab (TAKHZYRO) is a plasma kallikrein inhibitor. Associated with Lacuna Pharma Pty Ltd.
Key facts
INN lanadelumab
Brand TAKHZYRO
Mechanism Plasma kallikrein inhibitor
Target Plasma kallikrein
Therapeutic class Blood and blood forming organs (B06)
ATC code B06AC05
Originator Lacuna Pharma Pty Ltd
Mechanism of action
Plasma kallikrein inhibitor
Primary target: Plasma kallikrein
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lanadelumab?
lanadelumab (TAKHZYRO) is a plasma kallikrein inhibitor. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for lanadelumab?
TAKHZYRO is a marketed brand name for lanadelumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.